Individuals with type 1 diabetes (T1D) have higher risks of cardiovascular disease and chronic kidney disease compared with individuals without diabetes1. Despite advances in glycemic management, 31% and 7% of…
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive effects on…
CureusComparative Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Versus Glucagon-Like Peptide-1 (GLP-1) Agonists on Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Network Meta-AnalysisSodium-glucose cotransporter-2 (SGLT2) inhibitors…
Specialty Please choose I’m not a medical professional. Allergy and Immunology Anatomy Anesthesiology Biostatistics Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health…
In a multinational, retrospective cohort study of 214,442 people living with type 2 diabetes without evidence of neurodegenerative disorders, the initiation of GLP-1 RAs was associated with a 19% relative…
CureusCardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-AnalysisType 2 diabetes mellitus (T2DM) markedly increases the risk of cardiovascular and renal complications, emphasizing…
For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic retinopathy (DR) and with a…
In this week’s issue of The Savvy Diabetic: 1st Rapid-Acting Biosimilar Insulin Approved UVa AI-Powered Insulin Delivery Susvimo for Diabetic Macular Edema Oral Insulin Prevention Trial (PDF) GLP-1 Agonists Increased…